Posted by Michael Wonder on 29 Jun 2023
Zai Lab announces NDA acceptance of repotrectinib for patients with ROS1 positive NSCLC by China’s NMPA
28 June 2023 - Zai Lab today announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1 positive non-small-cell lung cancer.
In May 2023, the Center for Drug Evaluation of China’s NMPA granted priority review to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer.
